In preclinical models of melanoma and colon carcinoma, PD-1 blockade enhanced the effectiveness of granulocyte macrophage colony stimulating factor (GM-CSF)-secreting tumor cells immunotherapy by increasing survival of tumor-bearing mice and by enhancing antigen-specific immune responses [177]. The gene discussed is PDCD1; the disease is colon carcinoma.